Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland.
Pract Radiat Oncol. 2019 Mar;9(2):e172-e179. doi: 10.1016/j.prro.2018.10.003. Epub 2018 Oct 17.
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making.
水凝胶直肠间隔器(HRS)是一种已获得美国食品和药物管理局批准的医疗器械,可增加前列腺与直肠之间的距离。我们进行了一项成本效益分析,以评估 HRS 在接受外束放射治疗(EBRT)的前列腺癌(PC)患者中减少放射治疗(RT)毒性的效果。
从美国支付者的角度出发,构建了一个多状态马尔可夫模型,以检查接受 EBRT 的局限性 PC 男性患者中 HRS 的成本效益(EBRT 单独与 EBRT+HRS)。分析的亚组包括 HRS 放置部位(医院门诊、医生办公室、门诊手术中心)和基线勃起功能良好的患者比例。EF、胃肠道和泌尿生殖系统毒性发生率以及与 HRS 植入相关的潜在风险数据来自最近发表的一项随机临床试验。健康效用和成本来自文献和 2018 年医师费用表,并按每年 3%贴现。从接受 RT 开始,对 5 年期间的质量调整生命年(QALY)和成本进行建模。进行了概率敏感性分析和基于价值的阈值分析。
在医院门诊环境中使用的每个患者 5 年的增量成本为 3578 美元,增量效果为 0.0371 QALY。对于在医院接受 HRS 插入的 PC 患者,增量成本效益比为 96440 美元/QALY;对于在门诊设施接受 HRS 插入的患者,增量成本效益比为 39286 美元/QALY。对于基线 EF 良好的男性,在医院门诊和门诊设施中,增量成本效益比分别为 35548 美元/QALY 和 9627 美元/QALY。
根据当前的 Medicare 医师费用表,HRS 在支付意愿阈值为 100000 美元时具有成本效益。这些结果存在很大的不确定性,表明需要更多的证据来完善未来的决策。